These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 32513296)

  • 21. Whole Genome Sequencing-Based Discovery of Structural Variants in Glioblastoma.
    Wrzeszczynski KO; Felice V; Shah M; Rahman S; Emde AK; Jobanputra V; O Frank M; Darnell RB
    Methods Mol Biol; 2018; 1741():1-29. PubMed ID: 29392687
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A comprehensive prognostic signature for glioblastoma patients based on transcriptomics and single cell sequencing.
    Fan F; Zhang H; Dai Z; Zhang Y; Xia Z; Cao H; Yang K; Hu S; Guo Y; Ding F; Cheng Q; Zhang N
    Cell Oncol (Dordr); 2021 Aug; 44(4):917-935. PubMed ID: 34142341
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multi-omics analysis of primary glioblastoma cell lines shows recapitulation of pivotal molecular features of parental tumors.
    Rosenberg S; Verreault M; Schmitt C; Guegan J; Guehennec J; Levasseur C; Marie Y; Bielle F; Mokhtari K; Hoang-Xuan K; Ligon K; Sanson M; Delattre JY; Idbaih A
    Neuro Oncol; 2017 Feb; 19(2):219-228. PubMed ID: 27571888
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Next generation sequencing of chromosomal rearrangements in patients with split-hand/split-foot malformation provides evidence for DYNC1I1 exonic enhancers of DLX5/6 expression in humans.
    Lango Allen H; Caswell R; Xie W; Xu X; Wragg C; Turnpenny PD; Turner CL; Weedon MN; Ellard S
    J Med Genet; 2014 Apr; 51(4):264-7. PubMed ID: 24459211
    [TBL] [Abstract][Full Text] [Related]  

  • 25. TERT promoter wild-type glioblastomas show distinct clinical features and frequent PI3K pathway mutations.
    Williams EA; Miller JJ; Tummala SS; Penson T; Iafrate AJ; Juratli TA; Cahill DP
    Acta Neuropathol Commun; 2018 Oct; 6(1):106. PubMed ID: 30333046
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Widely metastatic glioblastoma with BRCA1 and ARID1A mutations: a case report.
    Umphlett M; Shea S; Tome-Garcia J; Zhang Y; Hormigo A; Fowkes M; Tsankova NM; Yong RL
    BMC Cancer; 2020 Jan; 20(1):47. PubMed ID: 31959133
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Unique genome-wide map of TCF4 and STAT3 targets using ChIP-seq reveals their association with new molecular subtypes of glioblastoma.
    Zhang JX; Zhang J; Yan W; Wang YY; Han L; Yue X; Liu N; You YP; Jiang T; Pu PY; Kang CS
    Neuro Oncol; 2013 Mar; 15(3):279-89. PubMed ID: 23295773
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Aggressive Treatment in Glioblastoma: What Determines the Survival of Patients?
    Yu L; Zhang G; Qi S
    J Neurol Surg A Cent Eur Neurosurg; 2021 Mar; 82(2):112-117. PubMed ID: 33157564
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immune genes are associated with human glioblastoma pathology and patient survival.
    Vauléon E; Tony A; Hamlat A; Etcheverry A; Chiforeanu DC; Menei P; Mosser J; Quillien V; Aubry M
    BMC Med Genomics; 2012 Sep; 5():41. PubMed ID: 22980038
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comprehensive genetic alteration profiling in primary and recurrent glioblastoma.
    Neilsen BK; Sleightholm R; McComb R; Ramkissoon SH; Ross JS; Corona RJ; Miller VA; Cooke M; Aizenberg MR
    J Neurooncol; 2019 Mar; 142(1):111-118. PubMed ID: 30535594
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The prognostic impact of TERT promoter mutations in glioblastomas is modified by the rs2853669 single nucleotide polymorphism.
    Batista R; Cruvinel-Carloni A; Vinagre J; Peixoto J; Catarino TA; Campanella NC; Menezes W; Becker AP; de Almeida GC; Matsushita MM; Clara C; Neder L; Viana-Pereira M; Honavar M; Castro L; Lopes JM; Carvalho B; Vaz RM; Máximo V; Soares P; Sobrinho-Simões M; Reis RM; Lima J
    Int J Cancer; 2016 Jul; 139(2):414-23. PubMed ID: 26914704
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of a multidimensional transcriptome signature for survival prediction of postoperative glioblastoma multiforme patients.
    Gao WZ; Guo LM; Xu TQ; Yin YH; Jia F
    J Transl Med; 2018 Dec; 16(1):368. PubMed ID: 30572911
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapy.
    Nguyen HN; Lie A; Li T; Chowdhury R; Liu F; Ozer B; Wei B; Green RM; Ellingson BM; Wang HJ; Elashoff R; Liau LM; Yong WH; Nghiemphu PL; Cloughesy T; Lai A
    Neuro Oncol; 2017 Mar; 19(3):394-404. PubMed ID: 27571882
    [TBL] [Abstract][Full Text] [Related]  

  • 34. TERT promoter mutations and rs2853669 polymorphism: prognostic impact and interactions with common alterations in glioblastomas.
    Nencha U; Rahimian A; Giry M; Sechi A; Mokhtari K; Polivka M; Schmitt Y; Di Stefano AL; Alentorn A; Labussière M; Sanson M
    J Neurooncol; 2016 Feb; 126(3):441-6. PubMed ID: 26608520
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Telomerase reverse transcriptase promoter alterations across cancer types as detected by next-generation sequencing: A clinical and molecular analysis of 423 patients.
    Schwaederle M; Krishnamurthy N; Daniels GA; Piccioni DE; Kesari S; Fanta PT; Schwab RB; Patel SP; Parker BA; Kurzrock R
    Cancer; 2018 Mar; 124(6):1288-1296. PubMed ID: 29211306
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New prognostic factor telomerase reverse transcriptase promotor mutation presents without MR imaging biomarkers in primary glioblastoma.
    Ersoy TF; Keil VC; Hadizadeh DR; Gielen GH; Fimmers R; Waha A; Heidenreich B; Kumar R; Schild HH; Simon M
    Neuroradiology; 2017 Dec; 59(12):1223-1231. PubMed ID: 28894890
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genetic, epigenetic, and molecular landscapes of multifocal and multicentric glioblastoma.
    Liu Q; Liu Y; Li W; Wang X; Sawaya R; Lang FF; Yung WK; Chen K; Fuller GN; Zhang W
    Acta Neuropathol; 2015 Oct; 130(4):587-97. PubMed ID: 26323991
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Somatic mutations in myeloid cell leukemia-1 contribute to the pathogenesis of glioma by prolonging its half-life.
    Lv X; Tan G; Yao Y; Lv L; Deng X; Dong L; Li S; Li L; Xu Y
    Mol Med Rep; 2015 Jul; 12(1):1265-71. PubMed ID: 25777305
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cerebellar glioblastoma: a clinical series with contemporary molecular analysis.
    Hong B; Banan R; Christians A; Nakamura M; Lalk M; Lehmann U; Hartmann C; Krauss JK
    Acta Neurochir (Wien); 2018 Nov; 160(11):2237-2248. PubMed ID: 30203362
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CNCDatabase: a database of non-coding cancer drivers.
    Liu EM; Martinez-Fundichely A; Bollapragada R; Spiewack M; Khurana E
    Nucleic Acids Res; 2021 Jan; 49(D1):D1094-D1101. PubMed ID: 33095860
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.